Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs Zai Lab Limited Unsponsored ADR (ZLAB)

NewAmsterdam Pharma Company N.V. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Zai Lab Limited Unsponsored ADR are of similar size ($2.7B and $2.5B). Zai Lab Limited Unsponsored ADR grew revenue faster over the last twelve months: 5.10% against −88.9%. Zai Lab Limited Unsponsored ADR has the higher net margin (−41.9% vs −3,644.2%) and the lower return on invested capital (−129.3% vs 0.00%). Across the 17 metrics below, Zai Lab Limited Unsponsored ADR leads on 11 and NewAmsterdam Pharma Company N.V. on 6.

Valuation

Metric NAMS ZLAB Biotechnology median
P/E n/m n/m 8.50
P/S 343.55 5.78 9.71
P/B 3.87 4.28 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 254.35 4.71 9.21
Earnings yield (10.89%) (7.35%) (33.15%)
Free cash flow yield (5.87%) (6.25%) (25.50%)

Profitability

Metric NAMS ZLAB Biotechnology median
Gross margin 100.00% 56.47% 65.16%
Operating margin (3,432.20%) (58.74%) 0.00%
Net margin (3,644.21%) (41.86%) 0.00%
Free cash flow margin (2,018.28%) (36.13%) 0.00%
Return on equity (36.81%) (26.91%) (56.36%)
Return on assets (34.16%) (16.81%) (48.04%)
Return on invested capital 0.00% (129.34%) 0.00%

Growth

Metric NAMS ZLAB Biotechnology median
Revenue growth (TTM) (88.87%) 5.10% 6.02%
EPS growth (last fiscal year) 32.81% 38.46% 30.26%
Revenue growth, 5-year CAGR — 56.54% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS ZLAB Biotechnology median
Debt to equity 0.00 0.39 0.00
Current ratio 9.03 2.13 4.72
Net debt to EBITDA 2.83 2.66 0.96

Dividend

Metric NAMS ZLAB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NAMS ZLAB Biotechnology median
Market cap 2.46b 2.65b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack